Table 1.
Pooled demographic and baseline characteristics
| TA-ER 32 mg N = 324 |
Saline-placebo N = 262 |
TAcs 40 mg N = 212 |
|
|---|---|---|---|
| Sex, n (%) | |||
| Male | 139 (42.9) | 105 (40.1) | 86 (40.6) |
| Female | 185 (57.1) | 157 (59.9) | 126 (59.4) |
| Age, years, mean (SD) | 60.5 (9.16) | 61.4 (8.73) | 62.1 (10.06) |
| Race, n (%) | |||
| American Indian or Alaska Native | 0 | 1 (0.4) | 0 |
| Asian | 23 (7.1) | 15 (5.7) | 18 (8.5) |
| Black or African American | 26 (8.0) | 19 (7.3) | 13 (6.1) |
| Native Hawaiian or other Pacific Islander | 4 (1.2) | 1 (0.4) | 2 (0.9) |
| White | 269 (83.0) | 226 (86.3) | 178 (84.0) |
| Other | 2 (0.6) | 0 | 1 (0.5) |
| BMI (kg/m2), mean (SD) | 30.55 (4.771) | 30.58 (4.871) | 30.15 (4.864) |
| BMI category, n (%) | |||
| Normal (18.0–24.9 kg/m2) | 43 (13.3) | 32 (12.2) | 34 (16.0) |
| Overweight (25.0–29.9 kg/m2) | 114 (35.2) | 91 (34.7) | 69 (32.5) |
| Class I obese (30.0–34.9 kg/m2) | 100 (30.9) | 81 (30.9) | 72 (34.0) |
| Class II obese (35.0–39.9 kg/m2) | 65 (20.1) | 57 (21.8) | 37 (17.5) |
| Morbid obesity (≥ 40.0 kg/m2) | 2 (0.6) | 1 (0.4) | 0 |
| Years since primary diagnosis, mean (SD) | 7.10 (6.736) | 6.50 (5.781) | 7.35 (6.944) |
| Kellgren–Lawrence grade, n (%) | |||
| 2 | 127 (39.2) | 106 (40.5) | 88 (41.5) |
| 3 | 197 (60.8) | 156 (59.5) | 123 (58.0) |
| 4 | 0 | 0 | 1 (0.5) |
| Weekly average daily pain intensity score | |||
| 5–5.9 | 118 (36.4) | 99 (37.8) | 82 (38.7) |
| 6–6.9 | 107 (33.0) | 78 (29.8) | 70 (33.0) |
| ≥ 7 | 99 (30.6) | 85 (32.4) | 60 (28.3) |
BMI body mass index, SD standard deviation, TAcs triamcinolone acetonide crystalline suspension, TA-ER triamcinolone acetonide extended-release